Renew Biopharma Announces Landmark Patent in Cannabinoid Biosynthesis; CEO to Speak Today at SynBioBeta
SAN FRANCISCO–(BUSINESS WIRE)–Renew Biopharma, a pre-clinical startup drug company developing new, proprietary small molecules to improve human health — focused particularly on neurotherapeutics — today announced a new landmark patent covering the extensive enzyme engineering of the key step for the production of cannabinoids and cannabinoid derivatives using microbial biosynthesis. This key step is governed…
Details